News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
European Regulators Recommend Biogen Idec, Inc. (Massachusetts)'s (JOBS) Tysabri Label Update
January 22, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- European regulators have identified 31 cases of a potentially deadly brain infection in patients taking Biogen Idec Inc's (BIIB.O) multiple sclerosis drug Tysabri and recommended new measures for dealing with the risks of the drug.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Biogen
MORE ON THIS TOPIC
Neurodegeneration
Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%
October 30, 2026
·
2 min read
·
Gabrielle Masson
Drug Development
Dren Bio lands $350M to push rare blood cancer therapy toward market
October 29, 2026
·
2 min read
·
Gabrielle Masson
Earnings
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
October 29, 2026
·
4 min read
·
Gabrielle Masson
Neuroscience
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
October 29, 2026
·
1 min read
·
Annalee Armstrong